Prolytic is being integrated into the Kymos Group to offer added value services to biopharmaceutical companies worldwide, with a pan-European solution in a rapidly-changing business environment.   The combination of expertise will allow the companies to broaden their portfolio into a unique selection of services for innovative small and large molecules, generics, biosimilars, antibodies, biomarkers, ADA (anti-drug antibodies), ADC (antibody-drug conjugates), hormones, enzymes and nucleic acids. ...